The occurrence and development of PTCL after delivery with the shift from CD4 positivity to CD8 positivity may be associated with not only the selection of resistant subclone as a result of chemotherapy but also the changes of immune status before and after delivery. This evidence concerns the gene CD4 and mature T-cell and NK-cell non-Hodgkin lymphoma.